---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-124279"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T12:15:59.389341+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apogee: APG808 Phase 1 shows 55-day half-life; APG777 data support annual dosing; Phase 2 topline now mid-2025

## Summary
- APG808 interim Phase 1: half-life ~55 days, supports every 2-3 month dosing; well-tolerated; Phase 1b in asthma expected 1H 2025.
- APG777 Phase 1 12-month data: half-life 77 days, near complete pSTAT6 inhibition, supports potential annual dosing in AD.
- APG777 Phase 2 Part A 16-week topline data accelerated to mid-2025 due to strong enrollment.
- Preclinical PoC for APG777+APG990 combo: Phase 1b vs DUPIXENT in AD planned for 2025, data 2H 2026.
- APG333 (anti-TSLP) Phase 1 start by end 2024; combo with APG777 in asthma/COPD under planning.

## SEC filing metadata
- accession: 0001104659-24-124279
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465924124279/0001104659-24-124279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465924124279/tm2429855d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-124279
- JSON: https://secwatch.observer/filing/0001104659-24-124279.json
- Plain text: https://secwatch.observer/filing/0001104659-24-124279.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.